Who we are
Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
At a glance
Our company by the numbers
50,129,284
Patients with neurodegenerative diseases
42
Employees living and working across the world
58%
Improvement in memory functions for clinical trial patients
2016
Year we were officially founded
Meet the team
You?
Recognized and proud
Latest news and updates
Stay up to date
Jan 20, 2023
The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease
Dec 1, 2022
Startup’s Headset to Treat Alzheimer’s Will Undergo Wide Trial With Patients
Aug 3, 2022
Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study
May 2, 2022